Other (Income)/Deductions - Net (Footnotes) (Details) - USD ($) $ in Millions			1 Months Ended	3 Months Ended		9 Months Ended
		Apr. 08, 2016	Jul. 31, 2016	Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016		Sep. 27, 2015	Oct. 06, 2016	Apr. 03, 2016
Loss Contingencies [Line Items]
Gain on sale of investments								$ 160
Impairment of intangible assets				$ 126	$ 163	$ 767		163
Payments of merger termination costs		$ 150				150
Income from contract resolution						116
Hisun Pfizer Pharmaceuticals Co. Ltd [Member]
Loss Contingencies [Line Items]
Equity method investment, impairment					470	$ 211		470
Equity method investment, ownership percentage				49.00%		49.00%				49.00%
Laboratorio Teuto Brasilero [Member]
Loss Contingencies [Line Items]
Equity method investment, impairment						$ 50
Equity method investment, ownership percentage				40.00%		40.00%
Pending Litigation [Member] | Celebrex and Bextra [Member] | Product Safety Misrepresentation [Member]
Loss Contingencies [Line Items]
Litigation settlement			$ 486			$ 486
In Process Research and Development [Member]
Loss Contingencies [Line Items]
Impairment of intangible assets					28			28
Impairment, indefinite-lived intangible assets	[1]					436
In Process Research and Development [Member] | Hospira [Member]
Loss Contingencies [Line Items]
Impairment of intangible assets						265
In Process Research and Development [Member] | InnoPharma [Member]
Loss Contingencies [Line Items]
Impairment of intangible assets				$ 97
Other In Process Research and Development [Member]
Loss Contingencies [Line Items]
Impairment of intangible assets						74
Other In Process Research and Development [Member] | Hospira [Member]
Loss Contingencies [Line Items]
Impairment of intangible assets						45
Other In Process Research and Development [Member] | King [Member]
Loss Contingencies [Line Items]
Impairment of intangible assets						29
Trade Names [Member]
Loss Contingencies [Line Items]
Impairment, indefinite-lived intangible assets					20			20
Operating Segments [Member] | EH [Member]
Loss Contingencies [Line Items]
Impairment of intangible assets				97	143	738		143
Operating Segments [Member] | IH [Member]
Loss Contingencies [Line Items]
Impairment of intangible assets				$ 29	20			20
Held-for-sale [Member] | ICU Medical [Member] | HIS [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Consideration transferred									$ 1,000
Developed Technology Rights [Member]
Loss Contingencies [Line Items]
Impairment, finite-lived intangible assets					$ 115	331	[1]	115
Developed Technology Rights [Member] | Hospira [Member]
Loss Contingencies [Line Items]
Impairment of intangible assets						331
Distribution Rights [Member]
Loss Contingencies [Line Items]
Gain on disposition of intangible assets						$ 49		$ 76

[1] Reflects intangible assets written down to fair value in the first nine months of 2016. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product and the impact of technological risk associated with IPR&D assets; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.